BOSTON, Mass. (November 17, 2020) – HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery and development of first-in-class allosteric therapies targeting nature’s regulatory sites, today announced the appointment of industry leader, Eva Jack, to Chief Operating Officer. Ms. Jack will work with the leadership team to shape corporate strategy and company growth and development. She joins from Mersana Therapeutics where she was Chief Business Officer.
“I am thrilled to welcome Eva to the HotSpot leadership team,” said Jonathan Montagu, Co-founder and Chief Executive Officer of HotSpot Therapeutics. “She is an incredibly well-rounded leader who brings a valuable combination of business strategy and financial expertise, as well as deep experience in oncology. Eva joins at an important time for the company, as we advance our pipeline and pursue strategic partnerships to deliver first-in-class allosteric medicines to patients.”
Ms. Jack served as Chief Business Officer at Mersana Therapeutics for the past six years, where her leadership helped transform the company from an early-stage start-up to a publicly traded, clinical-stage organization. Prior to that time, she owned and operated Macava Consulting, a firm offering business strategy and financial consulting services to biotech companies. She previously served as the Chief Business Officer at Pulmatrix and before that was at MedImmune (acquired by AstraZeneca). While at MedImmune Ms. Jack was Managing Director of MedImmune Ventures, where she was responsible for making and managing investments in private biotechnology companies. Prior to MedImmune Ventures, she was in MedImmune’s Business Development group, where she was responsible for in-licensing, out-licensing and research collaborations. Ms. Jack has also held various positions at Intel Corp. in venture investments, corporate strategy and public policy. Ms. Jack earned her BA from the University of Virginia and an MS in Health Sciences from The Johns Hopkins University.
“HotSpot is truly an exciting company. The team has made incredible progress in validating its technology platform and charting the path forward to advance a pipeline of highly differentiated therapies. I’m excited to join at this important stage in the company’s development as we rapidly progress to the clinic and evolve the organization to become a fully integrated biotechnology company,” said Ms. Jack, Chief Operating Officer of HotSpot Therapeutics.
HotSpot Therapeutics is creating a new paradigm for allosteric medicines that exploits a protein’s natural control mechanisms. Leveraging a deep understanding of protein structure-function, the company’s SpotFinder™ platform identifies critical regulatory regions on proteins – “regulatory hotspots” – that are amenable to small molecule drug discovery. This allows HotSpot to design first-in-class allosteric medicines with superior pharmacology, selectivity and drug-like properties across a number of target classes – kinases, E3 ligases and transcription factors.
About HotSpot Therapeutics
HotSpot Therapeutics is targeting nature’s regulatory mechanisms to create allosteric medicines that exhibit high precision and potency. The company leverages its proprietary SpotFinder™ technology, the first and only platform designed to identify and target “regulatory hotspots,” a unique family of pockets that sit remote from the active site on a protein and are used by nature to control protein function. Using bespoke chemistry approaches, HotSpot is developing a pipeline of first-in-class small molecules for the treatment of autoimmune and rare diseases as well as cancer. The company has identified regulatory hotspots across multiple target classes including kinases, transcription factors and E3 ligases. HotSpot’s lead compounds include the first and only allosteric inhibitors to target PKC-theta for autoimmune diseases and S6 kinase, a critical signaling node involved in the regulation of mitochondrial and metabolic function. To learn more, visit www.hotspotthera.com.